The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Ebselen Protects Both Gray and White Matter in a Rodent Model of Focal Cerebral Ischemia
Abstract
Background and Purpose — The neuroprotective efficacy of an intravenous formulation of the antioxidant ebselen has been comprehensively assessed with specific regard to conventional quantitative histopathology, subcortical axonal damage, neurological deficit, and principal mechanism of action. Methods — Transient focal ischemia (2 hours of intraluminal thread-induced ischemia with 22 hours of reperfusion) was induced in the rat. Ebselen (1 mg/kg bolus plus 1 mg/kg per hour IV) or vehicle was administered at the start of reperfusion and continued to 24 hours. Neurological deficit was assessed 24 hours after ischemia. Gray matter damage was evaluated by quantitative histopathology. Axonal damage was determined with amyloid precursor protein immunohistochemistry used as a marker of disrupted axonal flow and Tau-1 immunohistochemistry to identify oligodendrocyte pathology. Oxidative damage was determined by 8-hydroxy-2′-deoxyguanosine (8-OHdG) and 4-hydroxynonenal (4-HNE) immunohistochemistry. Results — Ebselen significantly reduced the volume of gray matter damage in the cerebral hemisphere (by 53.6% compared with vehicle, P <0.02). Axonal damage was reduced by 46.8% ( P <0.002) and the volume of oligodendrocyte pathology was reduced by 60.9% ( P <0.005). The neurological deficit score was reduced by 40.7% ( P <0.05) and the volume of tissue immunopositive for 8-OHdG and 4-HNE was reduced by 65% ( P <0.002) and 66% ( P <0.001), respectively, in ebselen-treated animals. Conclusions — Delayed (2-hour) treatment with intravenous ebselen significantly reduced gray and white matter damage and neurological deficit associated with transient ischemia. The reduction in tissue displaying evidence of oxidative stress suggests that the major mechanism of action is attenuation of free radical damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The changing landscape of ischaemic brain injury mechanisms
Lee, J.-M., Zipfel, G. J., & Choi, D. W. (1999) · Nature · doi:10.1038/399a007 · Cited by 1,102
Experimental studies of ischemic brain edema
Koizumi, J.-I., Yoshida, Y., Nakazawa, T., & Ooneda, G. (1986) · Nosotchu · doi:10.3995/jstroke.8.1 · Cited by 996
Cited by
Neuroprotection for ischemic stroke: Past, present and future
Ginsberg, M. D. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.007 · Cited by 779
Jurk, D., Wang, C., Miwa, S., Maddick, M., Korolchuk, V., Tsolou, A., Gonos, E. S., Thrasivoulou, C., Jill Saffrey, M., Cameron, K., et al. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00870.x · Cited by 598
Toxicology and pharmacology of selenium: emphasis on synthetic organoselenium compounds
Nogueira, C. W., & Rocha, J. B. T. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0720-3 · Cited by 477
Pathophysiologic Cascades in Ischemic Stroke
Xing, C., Arai, K., Lo, E. H., & Hommel, M. (2012) · International Journal of Stroke · doi:10.1111/j.1747-4949.2012.00839.x · Cited by 416
Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways
Azad, G. K., & Tomar, R. S. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3417-x · Cited by 343
Metadata
- Authors
- Imai, H., Masayasu, H., Dewar, D., Graham, D. I., & Macrae, I. M.
- Venue
- Stroke
- Published
- 2001-09
- Volume
- 32
- Issue
- 9
- Pages
- 2149-2154
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2142088831
- Cited by
- 177
- References
- 2
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ebselen Protects Both Gray and White Matter in a Rodent Model of Focal Cerebral Ischemia. https://app.cochat.ai/papers/10.1161/hs0901.095725
- The paper
- Imai, H., Masayasu, H., Dewar, D., Graham, D. I., & Macrae, I. M. (2001). Ebselen Protects Both Gray and White Matter in a Rodent Model of Focal Cerebral Ischemia. Stroke. https://doi.org/10.1161/hs0901.095725
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.